-$0.21 EPS Expected for Apollo Endosurgery, Inc. (NASDAQ:APEN) This Quarter

Wall Street brokerages expect that Apollo Endosurgery, Inc. (NASDAQ:APEN – Get Rating) will announce earnings per share of ($0.21) for the current quarter, Zacks reports. Two analysts have issued estimates for Apollo Endosurgery’s earnings, with the highest EPS estimate coming in at ($0.16) and the lowest estimate coming in at ($0.27). Apollo Endosurgery posted earnings per share of ($0.17) during the same quarter last year, which indicates a negative year-over-year growth rate of 23.5%. The company is expected to announce its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Apollo Endosurgery will report full-year earnings of ($0.87) per share for the current year, with EPS estimates ranging from ($1.22) to ($0.61). For the next fiscal year, analysts anticipate that the company will post earnings of ($0.81) per share, with EPS estimates ranging from ($1.13) to ($0.48). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Apollo Endosurgery.

Apollo Endosurgery (NASDAQ:APEN – Get Rating) last posted its earnings results on Tuesday, February 22nd. The biotechnology company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.07). The business had revenue of $16.17 million for the quarter, compared to analyst estimates of $16.17 million. Apollo Endosurgery had a negative return on equity of 148.35% and a negative net margin of 39.19%. During the same period in the previous year, the firm posted ($0.14) earnings per share.

APEN has been the topic of a number of research reports. Stifel Nicolaus decreased their price objective on Apollo Endosurgery from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, February 23rd. Cowen initiated coverage on Apollo Endosurgery in a report on Wednesday, December 15th. They issued an “outperform” rating and a $13.00 price objective on the stock. Piper Sandler decreased their price objective on Apollo Endosurgery from $14.00 to $12.00 in a report on Wednesday, February 23rd. Finally, Zacks Investment Research lowered Apollo Endosurgery from a “hold” rating to a “sell” rating in a report on Tuesday, February 1st. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $12.50.

In related news, CFO Jeffrey G. Black bought 15,000 shares of the business’s stock in a transaction dated Monday, February 28th. The stock was purchased at an average cost of $5.66 per share, for a total transaction of $84,900.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 26.20% of the company’s stock.

Several large investors have recently added to or reduced their stakes in APEN. Bank of America Corp DE bought a new stake in shares of Apollo Endosurgery during the 4th quarter valued at $41,000. Lazard Asset Management LLC lifted its position in shares of Apollo Endosurgery by 57.2% during the 4th quarter. Lazard Asset Management LLC now owns 6,142 shares of the biotechnology company’s stock worth $51,000 after buying an additional 2,236 shares during the last quarter. Barclays PLC lifted its position in shares of Apollo Endosurgery by 384.1% during the 3rd quarter. Barclays PLC now owns 6,772 shares of the biotechnology company’s stock worth $61,000 after buying an additional 5,373 shares during the last quarter. JPMorgan Chase & Co. bought a new stake in shares of Apollo Endosurgery during the 4th quarter worth $82,000. Finally, Trexquant Investment LP bought a new stake in shares of Apollo Endosurgery during the 3rd quarter worth $105,000. Hedge funds and other institutional investors own 91.54% of the company’s stock.

APEN stock opened at $5.75 on Friday. The company has a current ratio of 7.92, a quick ratio of 7.09 and a debt-to-equity ratio of 0.87. Apollo Endosurgery has a 1-year low of $4.52 and a 1-year high of $10.39. The business’s 50 day simple moving average is $5.93.

Apollo Endosurgery Company Profile (Get Rating)

Apollo Endosurgery, Inc, a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to sutures and secure the approximation of tissue through a flexible endoscope.

See Also